Therefore, investigating whether SLC16A1-AS1 can serve as a non-invasive tumor marker for early cancer diagnosis presents an intriguing research direction.The potential of SLC16A1-AS1 to predict disease progression, response to treatment, and patient outcomes offers substantial prospects for enhancing personalized cancer care. Here, SLC16A1 is linked to neoplasm.